相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer
Seong Yoon Yi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
Brian M. Wolpin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer
Joanna M. Brell et al.
ONCOLOGY (2009)
Literature Review October-December 2008
Kevin Carroll et al.
PHARMACEUTICAL STATISTICS (2009)
Second-Line Therapy in Refractory Pancreatic Cancer. Results of a Phase II Study
Uwe Pelzer et al.
ONKOLOGIE (2009)
Phase 2 Trial of Oxaliplatin Plus Capecitabine (XELOX) as Second-line Therapy for Patients With Advanced Pancreatic Cancer
Henry Q. Xiong et al.
CANCER (2008)
A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study
U. Pelzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers
Alex A. Adjei et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer
Matthew H. Kulke et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Clinical experience of MEK inhibitors in cancer therapy
Ding Wang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
A phase II study of docetaxel in combination with ZD1839 (gefitinib) in previously treated patients with metastatic pancreatic cancer
L. S. Blaszkowsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer:: a multicenter phase II trial
S. Boeck et al.
ANNALS OF ONCOLOGY (2007)
Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor
Tammie C. Yeh et al.
CLINICAL CANCER RESEARCH (2007)
Estimates of the cancer incidence and mortality in Europe in 2006
J. Ferlay et al.
ANNALS OF ONCOLOGY (2007)
Second-line chemotherapy in advanced pancreatic Carcinoma: a multicenter survey of the gruppo oncologico italia meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice
V. Gebbia et al.
ANNALS OF ONCOLOGY (2007)
Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
A Demols et al.
BRITISH JOURNAL OF CANCER (2006)
A Multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer
Michail Ignatiadis et al.
ONCOLOGY (2006)
Design issues of randomized phase II trials and a proposal for phase II screening trials
LV Rubinstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study
N Tsavaris et al.
INVESTIGATIONAL NEW DRUGS (2005)
Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: A pediatric oncology group study
AS Pappo et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer
M Cantore et al.
ONCOLOGY (2004)
Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma
H Ulrich-Pur et al.
BRITISH JOURNAL OF CANCER (2003)
Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer
TH Cartwright et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma
H Oettle et al.
ANTI-CANCER DRUGS (2000)
分享论文
